Cahill Wealth Management LLC Acquires 44,179 Shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Cahill Wealth Management LLC raised its holdings in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPTFree Report) by 23.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 232,263 shares of the company’s stock after acquiring an additional 44,179 shares during the quarter. ClearPoint Neuro makes up approximately 1.1% of Cahill Wealth Management LLC’s holdings, making the stock its 16th biggest position. Cahill Wealth Management LLC owned approximately 0.94% of ClearPoint Neuro worth $1,577,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in CLPT. Bank of New York Mellon Corp grew its stake in shares of ClearPoint Neuro by 3.2% in the third quarter. Bank of New York Mellon Corp now owns 63,036 shares of the company’s stock valued at $316,000 after buying an additional 1,932 shares in the last quarter. Lane Generational LLC grew its stake in shares of ClearPoint Neuro by 220.3% in the third quarter. Lane Generational LLC now owns 149,779 shares of the company’s stock valued at $750,000 after buying an additional 103,019 shares in the last quarter. CM Management LLC lifted its holdings in ClearPoint Neuro by 11.1% during the 3rd quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $1,002,000 after purchasing an additional 20,000 shares during the last quarter. SG Americas Securities LLC acquired a new stake in ClearPoint Neuro during the 3rd quarter valued at $83,000. Finally, Taylor Frigon Capital Management LLC lifted its holdings in ClearPoint Neuro by 43.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 353,868 shares of the company’s stock valued at $1,773,000 after purchasing an additional 107,441 shares during the last quarter. 30.08% of the stock is owned by institutional investors.

ClearPoint Neuro Stock Performance

ClearPoint Neuro stock traded down $0.39 during mid-day trading on Friday, hitting $5.81. 194,220 shares of the company’s stock traded hands, compared to its average volume of 148,431. ClearPoint Neuro, Inc. has a fifty-two week low of $4.05 and a fifty-two week high of $10.95. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.87 and a quick ratio of 3.80. The stock has a market cap of $157.28 million, a price-to-earnings ratio of -6.30 and a beta of 0.89. The firm has a 50 day simple moving average of $6.86 and a two-hundred day simple moving average of $6.30.

ClearPoint Neuro (NASDAQ:CLPTGet Free Report) last posted its earnings results on Tuesday, March 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. ClearPoint Neuro had a negative return on equity of 83.94% and a negative net margin of 92.21%. The company had revenue of $6.81 million during the quarter, compared to the consensus estimate of $6.40 million. On average, research analysts expect that ClearPoint Neuro, Inc. will post -0.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus reaffirmed a “buy” rating and set a $9.00 price target (up previously from $8.00) on shares of ClearPoint Neuro in a report on Wednesday, March 13th.

View Our Latest Stock Analysis on ClearPoint Neuro

ClearPoint Neuro Profile

(Free Report)

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

Recommended Stories

Institutional Ownership by Quarter for ClearPoint Neuro (NASDAQ:CLPT)

Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.